Labcorp agrees to buy select BioReference Health assets for $722 million plus earnout
Labcorp agreed to acquire select BioReference Health assets from OPKO Health for $722 million cash, subject to closing revenue adjustments. The deal includes the 4Kscore prostate cancer test, with up to $150 million in additional earnout payments tied to test revenue. Acquired assets include clinical and specialty test